Full text is available at the source.
Abstract
A novel self-amplifying mRNA vaccine, JJ-saRNA-HPV01, targets HPV16 E6/E7 and shows potential for improved immunogenicity.
- Self-amplifying mRNA vaccines may enable strong expression of antigens at lower doses compared to traditional vaccines.
- HPV16 is linked to various cancers, including cervical cancer, highlighting the need for effective vaccines.
- The study focuses on the immunogenicity and antitumor effectiveness of JJ-saRNA-HPV01 in a mouse model.
- Existing vaccines targeting HPV oncoproteins E6 and E7 have limited immune response and high production costs.
Simplified